Stay updated on CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial
Sign up to get notified when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.

Latest updates to the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page’s footer revision label was updated from **v3.5.2** to **v3.5.3**, indicating a site/version refresh rather than a change to the study record.SummaryDifference0.0%

- Check21 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check28 days agoNo Change Detected
- Check50 days agoChange DetectedRevision: v3.5.0 deployed.SummaryDifference0.0%

- Check57 days agoChange Detected- Revision updated from v3.4.2 to v3.4.3; no user-visible changes to the study page.SummaryDifference0.0%

- Check86 days agoChange DetectedA minor page revision was applied, moving from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check93 days agoChange DetectedOnly a page revision update from v3.4.0 to v3.4.1 is visible; no core content or study data changes were detected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.